SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenomics, Inc. on January 8, 2008, reporting events occurring on January 3, 2008. The registrant is a Florida corporation headquartered in New York. Note: The request metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the appointment of a new director to the Board of Directors.
- Appointment: Abba Poliakoff was appointed as a director on January 3, 2008.
- Term: He will serve until the next annual meeting of stockholders or until his successor is elected and qualified.
- Committee Assignment: Mr. Poliakoff will serve on the Compensation Committee.
- Background: Mr. Poliakoff is a member of the law firm Gordon, Feinblatt, Rothman, Hoffberger & Hollander, LLC, where he chairs the Business Law Department. He has prior experience with the SEC Division of Corporation Finance and specializes in corporate law, securities, and M&A.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the correct registrant name is Xenomics, Inc., not Cardiff Oncology, Inc.
- Confirm the effective date of Abba Poliakoff's directorship (January 3, 2008).
- Review the composition of the Compensation Committee following this appointment.
- Check for any potential conflicts of interest given Mr. Poliakoff's role as a corporate attorney and his service on other boards.